DE3782498D1 - Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. - Google Patents

Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.

Info

Publication number
DE3782498D1
DE3782498D1 DE8787905063T DE3782498T DE3782498D1 DE 3782498 D1 DE3782498 D1 DE 3782498D1 DE 8787905063 T DE8787905063 T DE 8787905063T DE 3782498 T DE3782498 T DE 3782498T DE 3782498 D1 DE3782498 D1 DE 3782498D1
Authority
DE
Germany
Prior art keywords
macrophage
granulocyt
medicine
producing
bacterial diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787905063T
Other languages
English (en)
Other versions
DE3782498T2 (de
Inventor
Howard Grabstein
J Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE3782498D1 publication Critical patent/DE3782498D1/de
Application granted granted Critical
Publication of DE3782498T2 publication Critical patent/DE3782498T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8787905063T 1986-07-30 1987-07-20 Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. Expired - Fee Related DE3782498T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/892,123 US5162111A (en) 1986-07-30 1986-07-30 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
PCT/US1987/001672 WO1988000832A1 (en) 1986-07-30 1987-07-20 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor

Publications (2)

Publication Number Publication Date
DE3782498D1 true DE3782498D1 (de) 1992-12-10
DE3782498T2 DE3782498T2 (de) 1993-03-18

Family

ID=25399410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787905063T Expired - Fee Related DE3782498T2 (de) 1986-07-30 1987-07-20 Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.

Country Status (8)

Country Link
US (1) US5162111A (de)
EP (1) EP0317568B1 (de)
JP (1) JP2735207B2 (de)
AT (1) ATE81984T1 (de)
AU (1) AU602526B2 (de)
CA (1) CA1297789C (de)
DE (1) DE3782498T2 (de)
WO (1) WO1988000832A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
NZ243953A (en) * 1989-01-30 1997-06-24 Schering Corp Gm-csf composition for treating leukocyte dysfunction
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5681862A (en) * 1993-03-05 1997-10-28 Buckman Laboratories International, Inc. Ionene polymers as microbicides
WO1995013089A1 (en) * 1993-11-10 1995-05-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
AU686842B2 (en) * 1994-08-19 1998-02-12 Embrex Inc. Method of treating birds with avian myelomonocytic growth factor
US6019965A (en) * 1994-10-24 2000-02-01 Ludwig Institute For Cancer Research Methods for treatment of pulmonary disease using GM-CSF
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000040269A2 (en) * 1999-01-05 2000-07-13 Lee Clarence C Pharmaceutical compositions for treatment of diseased tissues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6645740B1 (en) * 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
WO2006049599A1 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
JP2010508365A (ja) * 2006-11-03 2010-03-18 ダラグレキュル・アンパルトセルスカブ 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
JPS60209526A (ja) * 1984-04-04 1985-10-22 Denki Kagaku Kogyo Kk 高純度ｃｓｆの製造方法
JPS614506A (ja) * 1984-06-15 1986-01-10 Nitto Electric Ind Co Ltd ポリスルホン複合半透膜及びその製造方法
IE930961L (en) * 1984-07-06 1986-01-06 Sandoz Ag Lymphokine production and purification

Also Published As

Publication number Publication date
WO1988000832A1 (en) 1988-02-11
JPH02500270A (ja) 1990-02-01
EP0317568B1 (de) 1992-11-04
AU7751987A (en) 1988-02-24
DE3782498T2 (de) 1993-03-18
US5162111A (en) 1992-11-10
CA1297789C (en) 1992-03-24
EP0317568A4 (de) 1990-05-14
ATE81984T1 (de) 1992-11-15
EP0317568A1 (de) 1989-05-31
JP2735207B2 (ja) 1998-04-02
AU602526B2 (en) 1990-10-18

Similar Documents

Publication Publication Date Title
DE3782498D1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE102062T1 (de) Niederfrequenz-elektrotherapiegeraet.
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
ES2043890T3 (es) Nuevo uso medico.
CA2229479A1 (en) Method of promoting angiogenesis
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
KR890000108A (ko) 종양 치료용 약제학적 조성물
ATE83665T1 (de) Anwendung des humanblut-koagulationsfaktors-xiii zur behandlung von colitis gravis.
DE69226525T2 (de) Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
RU94022481A (ru) Способ определения иммуногенной активности биоактивных соединений и состав для его осуществления
DE3853427D1 (de) Behandlung gealterter haut mit oraler 13-cis-retinsäure.
DE69113802D1 (de) Anwendung von beta-alethin in zellkultur und therapie.
Kaplan The allantoin treatment of ulcers
ATE56147T1 (de) T-pa enthaltende medizinische zubereitung und deren verwendung.
SU1171035A1 (ru) Способ лечени сифилиса
DE3786442D1 (de) Verwendung von follikelreifungshormon zur herstellung eines therapeutischen mittels zur behandlung von neoplasmen von gonadalem ursprung.
RU2063774C1 (ru) Способ лечения хронических нарушений кровообращения
RU2014020C1 (ru) Способ лечения стилоидита
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
Schumer Recent advances in the management of burns
RU94001389A (ru) Способ лечения псориаза
RU92009328A (ru) Устройство для электротерапии
RU94026137A (ru) Способ лечения нейродермита
RU93037438A (ru) Способ лечения мышечно-тонического и нейро-дистрофического синдрома остеохондроза поясничного отдела позвоночника

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee